Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease

Abstract

The present invention relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases comprising the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

1 . A pharmaceutical composition for preventing or treating retinal disease comprising a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient: 
       
         
           
           
               
               
           
         
         in Chemical Formula 1, A is O or S; 
         R is a) straight or branched C 1  to C 5  alkyl unsubstituted, or independently or optionally substituted with 1 or 2 or more C 6  to C 10  aryl, b) benzyl unsubstituted, or independently or optionally substituted with 1 or 2 or more fluoro, chloro, bromo or straight or branched C 1  to C 4  alkoxy or c) benzyl substituted with hydroxycarbonyl; and 
         Y is H or a halogen element. 
       
     
     
         2 - 22 . (canceled) 
     
     
         23 . The pharmaceutical composition for preventing or treating retinal disease of  claim 1 , wherein the retinal disease is diabetic retinopathy or age-related macular disease. 
     
     
         24 . The pharmaceutical composition for preventing or treating retinal disease of  claim 1 , wherein the compound represented by the Chemical Formula 1 is a compound represented by Chemical Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         25 . The pharmaceutical composition for preventing or treating retinal disease of  claim 1 , wherein the pharmaceutical composition is an oral administration agent. 
     
     
         26 . The pharmaceutical composition for preventing or treating retinal disease of  claim 25 , further comprising at least one excipient selected from the group consisting of methyl cellulose (MC), dimethyl sulfoxide (DMSO), polyethylene glycol (PEG) and distilled water. 
     
     
         27 . The pharmaceutical composition for preventing or treating retinal disease of  claim 26 , wherein the excipient comprises 0.5 wt % of methyl cellulose. 
     
     
         28 . The pharmaceutical composition for preventing or treating retinal disease of  claim 25 , wherein the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof is filled in a capsule in powder form. 
     
     
         29 . The pharmaceutical composition for preventing or treating retinal disease of  claim 25 , wherein the compound represented by the Chemical Formula 1 is a compound represented by Chemical Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         30 . The pharmaceutical composition for preventing or treating retinal disease of  claim 1 , wherein the pharmaceutical composition is an eye drop. 
     
     
         31 . The pharmaceutical composition for preventing or treating retinal disease of  claim 30 , wherein the compound represented by the Chemical Formula 1 is a compound represented by Chemical Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         32 . A pharmaceutical composition for preventing or treating optic nerve disease comprising a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient: 
       
         
           
           
               
               
           
         
         in Chemical Formula 1, A is O or S; 
         R is a) straight or branched C 1  to C 5  alkyl unsubstituted, or independently or optionally substituted with 1 or 2 or more C 6  to C 10  aryl, b) benzyl unsubstituted, or independently or optionally substituted with 1 or 2 or more fluoro, chloro, bromo or straight or branched C 1  to C 4  alkoxy or c) benzyl substituted with hydroxycarbonyl; and 
         Y is H or a halogen element. 
       
     
     
         33 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 32 , wherein the optic nerve disease is selected from the group consisting of ischemic optic neuropathy, traumatic optic neuropathy, and compressive optic neuropathy. 
     
     
         34 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 32 , wherein the compound represented by the Chemical Formula 1 is a compound represented by Chemical Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         35 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 32 , the pharmaceutical composition is an oral administration agent. 
     
     
         36 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 35 , further comprising at least one excipient selected from the group consisting of methyl cellulose (MC), dimethyl sulfoxide (DMSO), polyethylene glycol (PEG) and distilled water. 
     
     
         37 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 36 , wherein the excipient comprises 0.5 wt % of methyl cellulose. 
     
     
         38 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 35 , wherein the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof is filled in a capsule in powder form. 
     
     
         39 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 35 , wherein the compound represented by the Chemical Formula 1 is a compound represented by Chemical Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         40 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 32 , the pharmaceutical composition is an eye drop. 
     
     
         41 . The pharmaceutical composition for preventing or treating optic nerve disease of  claim 40 , wherein the optic nerve disease is selected from the group consisting of ischemic optic neuropathy, traumatic optic neuropathy, and compressive optic neuropathy.